ArticlePharmacoEconomics - open2023

Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial.

F Felizzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.